In Silico Exploration of CD200 as a Therapeutic Target for COVID-19

Vladimir Perovic, Sanja Glisic, Milena Veljkovic, Slobodan Paessler, Veljko Veljkovic

Research output: Contribution to journalArticlepeer-review

Abstract

SARS-CoV-2, the pathogen causing COVID-19, continues to pose a significant threat to public health and has had major economic implications. Developing safe and effective vaccines and therapies offers a path forward for overcoming the COVID-19 pandemic. The presented study, performed by using the informational spectrum method (ISM), representing an electronic biology-based tool for analysis of protein–protein interactions, identified the highly conserved region of spike protein (SP) from SARS-CoV-2 virus, which is essential for recognition and targeting between the virus and its protein interactors on the target cells. This domain is suggested as a promising target for the drug therapy and vaccines, which could be effective against all currently circulating variants of SARS-CoV-2 viruses. The analysis of the virus/host interaction, performed by the ISM, also revealed OX-2 membrane glycoprotein (CD200) as a possible interactor of SP, which could serve as a novel therapeutic target for COVID-19 disease.

Original languageEnglish (US)
Article number1185
JournalMicroorganisms
Volume12
Issue number6
DOIs
StatePublished - Jun 2024
Externally publishedYes

Keywords

  • CD200
  • COVID-19
  • SARS-CoV-2
  • therapeutic target
  • vaccine
  • variants

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology

Fingerprint

Dive into the research topics of 'In Silico Exploration of CD200 as a Therapeutic Target for COVID-19'. Together they form a unique fingerprint.

Cite this